• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Charming Medical Limited

    1/6/26 4:01:28 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MCTA alert in real time by email
    6-K 1 ea0271964-6k_charming.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of January 2026

     

    Commission File Number: 001-42907

     

    Charming Medical Limited

     

    Units 1803-1806, 18/F, Hang Lung Centre
    2-20 Paterson Street, Causeway Bay, Hong Kong

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒    Form 40-F ☐

     

     

     

     

     

    On December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation.

     

    On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HK$240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company.

     

    The foregoing descriptions of our offer letter to Mr. Jiang are qualified in their entirety by reference to the full text thereof, which is attached as Exhibit 10.1 hereto and incorporated by reference herein.

     

    There are no family relationships between Mr. Jiang and any other employees of the Company or members of the Board of Directors.

     

    The biographical information of Mr. Jiang is set forth below:

     

    Yin Jiang, age 43

     

    Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co., Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China.

     

    1

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    10.1   Director offer letter to Mr. Yin Jiang, dated January 5, 2026

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Charming Medical Limited
         
    Date: January 6, 2026 By: /s/ Kit Wong
      Name:  Kit Wong
      Title: Chief Executive Officer and
        Chairman of the Board

     

    3

     

    Get the next $MCTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCTA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MCTA
    SEC Filings

    View All

    SEC Form 6-K filed by Charming Medical Limited

    6-K - Charming Medical Ltd (0002035992) (Filer)

    1/6/26 4:01:28 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Charming Medical Limited

    6-K - Charming Medical Ltd (0002035992) (Filer)

    11/28/25 7:00:30 AM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Charming Medical Limited

    6-K - Charming Medical Ltd (0002035992) (Filer)

    11/13/25 6:01:23 AM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care

    $MCTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Halts Charming Medical Limited

    NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) --  The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading is halted in Charming Medical Limited (NASDAQ:MCTA) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in MCTA from 04:00:00 on November 12, 2025 to 23:59:00 on November 25, 2025. The last sale price of the company's ordinary shares was $29.355.  More information about the SEC's order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104176.pdf. Trading will remain halted until Charming Medical Limited has fully satisfied Nasdaq's request for additional information. For news

    11/26/25 7:00:00 AM ET
    $MCTA
    $NDAQ
    Misc Health and Biotechnology Services
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

    HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (NASDAQ:MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering") of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") at a price of $4.00 per share (the "Public Offering Price"), Cathay Securities, Inc., the representative of the underwriters (the "Representative") of the Offering, has exercised its over-allotment option (the "Over-allotment") in full to purchase an additional 240,000 Class A Ordinary Shares at the Publ

    10/28/25 4:15:00 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care